

# Ihosvany Fernandez Bello

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1351997/ihosvany-fernandez-bello-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32  
papers

232  
citations

11  
h-index

15  
g-index

32  
ext. papers

287  
ext. citations

3.4  
avg, IF

2.72  
L-index

#	Paper	IF	Citations
32	Monitoring of new therapies for hemophilia.. <i>Blood Coagulation and Fibrinolysis</i> , <b>2022</b> , 33, S3-S4	1	
31	Clinical trials and Haemophilia during the COVID-19 pandemic: Madrid's experience. <i>Haemophilia</i> , <b>2020</b> , 26, e247-e249	3.3	5
30	Platelet and immune characteristics of immune thrombocytopaenia patients non-responsive to therapy reveal severe immune dysregulation. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 943-953	4.5	15
29	Thrombin Generation Related to Netosis in Patients with Systemic Lupus Erythematosus. <i>Blood</i> , <b>2020</b> , 136, 10-11	2.2	
28	Thein Vitro Procoagulant Effects of Standard and Extended Half-Life Recombinant Factor IX Concentrates in Patients on Prophylaxis with Emicizumab. <i>Blood</i> , <b>2020</b> , 136, 18-19	2.2	
27	Fibrin Polymerization Ability Influences Joint Condition in Patients with Severe Haemophilia. <i>Blood</i> , <b>2020</b> , 136, 17-18	2.2	
26	Procoagulant State of Sleep Apnea Depends on Systemic Inflammation and Endothelial Damage. <i>Archivos De Bronconeumologia</i> , <b>2020</b> , 58, 117-117	0.7	5
25	Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 645-659	7	19
24	Real Life Experience in Clinical Practice with Recombinant Coagulation FVIII-Fc Fusion Protein. <i>Blood</i> , <b>2019</b> , 134, 4929-4929	2.2	1
23	Prothrombotic State, Platelet Activation and Netosis in Systemic Lupus Erythematosus. <i>Blood</i> , <b>2019</b> , 134, 1141-1141	2.2	1
22	Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments. <i>Blood</i> , <b>2019</b> , 134, 1089-1089	2.2	
21	Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab. <i>Blood</i> , <b>2019</b> , 134, 1118-1118	2.2	
20	Immune thrombocytopenia - in defence of the platelet count. Response to Hill. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 130-131	4.5	
19	Platelet Protein Glycosylation in Immune Thrombocytopenia. <i>Blood</i> , <b>2018</b> , 132, 2437-2437	2.2	2
18	Platelet Dysfunction and Cellular Microparticles May be Involved in the Hipercoagulable State Observed in Obstructive Sleep Apnea Syndrome. <i>Blood</i> , <b>2018</b> , 132, 5048-5048	2.2	
17	Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFIT in patients with severe haemophilia A without inhibitors. <i>Haemophilia</i> , <b>2017</b> , 23, e50-e54	3.3	28
16	The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B. <i>Haemophilia</i> , <b>2017</b> , 23, 868-876	3.3	7

15	Procoagulant profile in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , <b>2016</b> , 175, 925-934	4.5	25
14	Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia. <i>Aids</i> , <b>2016</b> , 30, 1141-2	3.5	7
13	Endothelial Dysfunction and Altered Coagulation As Mediators of Thromboembolism in Behçet Disease. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2015</b> , 41, 621-8	5.3	17
12	Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 65-72	7	19
11	Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopenia. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 674-6	3.8	2
10	Features of Microparticle-Associated Procoagulant Activity in Patients with Thrombocytopenias of Immune and Central Origin. <i>Blood</i> , <b>2014</b> , 124, 1462-1462	2.2	
9	Behçet's disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity. <i>Orphanet Journal of Rare Diseases</i> , <b>2013</b> , 8, 81	4.2	12
8	Rotational thromboelastometry (ROTEM) in Behçet's disease. <i>Clinical Rheumatology</i> , <b>2013</b> , 32, 1691	3.9	
7	Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 909-19	7	11
6	Procoagulant Status In Patients With Immune Thrombocytopenia. <i>Blood</i> , <b>2013</b> , 122, 3528-3528	2.2	1
5	Effects Of Thrombopoietin Receptor Agonists On APRIL Plasma Levels In Patients With Immune Thrombocytopenia. <i>Blood</i> , <b>2013</b> , 122, 1083-1083	2.2	
4	Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 88-98	7	21
3	Thrombopoietin Receptor Agonist (ELTROMBOPAG) for Chronic Immune Thrombocytopenic Purpura (ITP) Treatment: 21 Patients in Only One Center. <i>Blood</i> , <b>2012</b> , 120, 4658-4658	2.2	
2	Clinical and genetic findings in five female patients with haemophilia A: Identification of a novel missense mutation, p.Phe2127Ser. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 718-23	7	12
1	Controversies and challenges in elective orthopedic surgery in patients with hemophilia and inhibitors. <i>Seminars in Hematology</i> , <b>2008</b> , 45, S64-7	4	22